Cumberland Pharmaceuticals (CPIX) Financials

Cumberland Pharmaceuticals logo
$5.58 +0.37 (+7.10%)
As of 12:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Cumberland Pharmaceuticals

Annual Income Statements for Cumberland Pharmaceuticals

This table shows Cumberland Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
0.73 -0.94 -7.98 -6.96 -3.54 -3.34 -3.51 -5.57 -6.28 -6.48 -2.84
Consolidated Net Income / (Loss)
0.67 -1.00 -8.05 -7.04 -3.55 -3.42 -3.60 -5.65 -6.33 -6.44 -2.86
Net Income / (Loss) Continuing Operations
0.67 -1.00 -8.05 -11 -9.21 -6.63 -5.60 -5.65 -6.33 -6.44 -2.86
Total Pre-Tax Income
1.25 -1.33 -3.87 -11 -9.29 -6.57 -5.56 -5.58 -6.28 -6.47 -2.81
Total Operating Income
1.11 -1.43 -4.08 -11 -9.29 -6.38 -7.68 -5.70 -9.55 -6.43 -2.79
Total Gross Profit
29 27 34 23 27 29 27 33 33 31 38
Total Revenue
34 33 41 29 34 37 36 42 40 38 45
Operating Revenue
33 33 41 29 34 37 36 42 40 38 45
Total Cost of Revenue
4.97 5.96 7.37 6.02 7.42 8.65 8.81 9.12 6.07 6.59 6.67
Operating Cost of Revenue
4.97 5.96 7.37 6.02 7.42 8.65 8.81 9.12 6.07 6.59 6.67
Total Operating Expenses
27 29 38 35 36 35 35 39 43 38 41
Selling, General & Admin Expense
7.61 8.56 9.65 10 9.97 10 9.78 10 11 11 12
Marketing Expense
14 15 21 14 15 15 15 17 18 17 19
Research & Development Expense
3.85 3.19 4.28 7.58 6.87 5.77 5.68 6.69 5.83 4.82 5.57
Amortization Expense
1.99 2.19 2.44 2.77 4.13 4.43 4.37 5.07 8.10 4.75 4.03
Total Other Income / (Expense), net
0.14 0.10 0.21 0.37 -0.00 -0.19 2.12 0.12 3.27 -0.03 -0.02
Interest Expense
0.07 0.11 0.09 0.20 0.25 0.26 0.10 0.59 0.67 0.61 0.50
Interest & Investment Income
0.21 0.20 0.30 0.56 0.24 0.08 0.03 0.10 0.29 0.33 0.48
Other Income / (Expense), net
- - - - 0.00 0.00 2.19 0.61 3.65 0.24 0.00
Income Tax Expense
0.58 -0.33 4.17 0.02 -0.08 0.06 0.03 0.07 0.05 -0.02 0.04
Other Gains / (Losses), net
- - - - - - - - - 0.00 -0.01
Net Income / (Loss) Attributable to Noncontrolling Interest
-0.06 -0.06 -0.07 -0.08 -0.01 -0.08 -0.10 -0.08 -0.05 0.04 -0.03
Basic Earnings per Share
$0.04 ($0.06) ($0.50) ($0.45) ($0.23) ($0.22) ($0.24) ($0.38) ($0.44) ($0.46) ($0.19)
Weighted Average Basic Shares Outstanding
16.72M 16.24M 15.91M 15.61M 15.40M 15.16M 14.90M 14.56M 14.30M 14.06M 14.85M
Diluted Earnings per Share
$0.04 ($0.06) ($0.50) ($0.45) ($0.23) ($0.22) ($0.24) ($0.38) ($0.44) ($0.46) ($0.19)
Weighted Average Diluted Shares Outstanding
17.09M 16.24M 15.91M 15.61M 15.40M 15.16M 14.90M 14.56M 14.30M 14.06M 14.85M
Weighted Average Basic & Diluted Shares Outstanding
18.30M 15.70M 16M 15.50M 15.18M 14.92M 14.84M 14.40M 14.18M 13.97M 14.96M

Quarterly Income Statements for Cumberland Pharmaceuticals

This table shows Cumberland Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-1.95 -1.09 -1.54 -1.90 1.26 -0.74 -1.94 -1.41 -3.29 -4.28 78
Consolidated Net Income / (Loss)
-1.90 -1.10 -1.54 -1.90 1.25 -0.74 -1.95 -1.43 -3.29 -4.27 78
Net Income / (Loss) Continuing Operations
-1.90 -1.10 -1.54 -1.90 1.25 -3.00 -2.73 -1.43 -3.29 -3.10 -1.12
Total Pre-Tax Income
-1.89 -1.09 -1.53 -1.96 1.25 -2.99 -2.72 -1.39 -3.14 -3.10 -1.12
Total Operating Income
-1.87 -1.03 -1.69 -1.84 1.29 -3.12 -2.86 -1.37 -3.13 -3.16 -1.94
Total Gross Profit
6.92 8.14 7.76 8.46 10 0.38 0.17 11 7.20 0.17 2.16
Total Revenue
8.50 9.85 9.09 10 12 0.38 0.17 14 9.13 0.17 2.16
Operating Revenue
8.50 9.85 9.09 10 12 0.38 0.17 14 9.13 0.17 2.16
Total Cost of Revenue
1.58 1.71 1.32 1.98 1.43 0.00 0.00 2.24 1.93 0.00 0.00
Total Operating Expenses
8.79 9.16 9.46 10 9.00 3.50 3.03 13 10 3.33 4.09
Selling, General & Admin Expense
2.37 2.76 2.68 3.33 2.46 2.66 2.38 4.04 2.55 2.55 2.18
Research & Development Expense
1.16 1.06 1.31 1.29 1.30 0.84 0.65 1.55 1.46 0.77 0.84
Amortization Expense
1.11 1.10 1.08 1.46 1.01 0.01 0.01 1.01 1.25 0.01 0.01
Other Operating Expenses / (Income)
- - - - - - 0.00 - - - 1.06
Total Other Income / (Expense), net
-0.02 -0.06 0.17 -0.12 -0.04 0.13 0.13 -0.02 -0.01 0.06 0.82
Interest Expense
0.12 0.13 0.14 0.22 0.16 0.00 0.00 0.11 0.09 0.00 0.00
Interest & Investment Income
0.10 0.06 0.07 0.11 0.13 0.13 0.13 0.09 0.08 0.06 0.82
Income Tax Expense
0.01 0.01 0.01 -0.06 0.01 0.01 0.01 0.02 0.00 0.00 0.00
Net Income / (Loss) Discontinued Operations
- - - - - - 0.78 - - - 79
Net Income / (Loss) Attributable to Noncontrolling Interest
0.04 -0.02 0.01 0.00 -0.01 0.01 -0.01 -0.02 0.00 0.00 0.00
Basic Earnings per Share
($0.14) ($0.08) ($0.11) ($0.13) $0.08 ($0.05) ($0.13) ($0.09) ($0.22) ($0.29) $5.19
Weighted Average Basic Shares Outstanding
14.10M 14.12M 14.05M 14.06M 14.94M 14.96M 14.96M 14.85M 14.96M 14.98M 14.99M
Diluted Earnings per Share
($0.14) ($0.08) ($0.11) ($0.13) $0.08 ($0.05) ($0.13) ($0.09) ($0.22) ($0.29) $5.07
Weighted Average Diluted Shares Outstanding
14.10M 14.12M 14.05M 14.06M 15.26M 14.96M 14.96M 14.85M 14.96M 14.98M 15.34M
Weighted Average Basic & Diluted Shares Outstanding
14.19M 14.10M 14.04M 13.97M 14.96M 14.96M 14.96M 14.96M 14.98M 14.98M 15.00M

Annual Cash Flow Statements for Cumberland Pharmaceuticals

This table details how cash moves in and out of Cumberland Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-1.66 -3.69 11 -17 0.27 -2.66 2.29 -7.28 -1.44 -0.36 -6.52
Net Cash From Operating Activities
5.88 0.57 -0.56 3.11 3.06 5.42 6.34 8.45 6.09 -0.61 4.93
Net Cash From Continuing Operating Activities
5.88 0.57 -0.56 -1.39 -2.46 1.90 4.35 8.45 6.09 -0.61 4.93
Net Income / (Loss) Continuing Operations
0.67 -1.00 -8.05 -11 -9.21 -6.63 -5.60 -5.65 -6.33 -6.44 -2.86
Consolidated Net Income / (Loss)
0.67 -1.00 -8.05 -7.04 -3.55 -3.42 -3.60 -5.65 -6.33 -6.44 -2.86
Depreciation Expense
2.25 2.40 2.65 2.98 4.40 4.75 4.61 5.33 4.94 4.90 4.15
Amortization Expense
0.05 0.08 0.08 0.10 0.05 0.05 0.03 0.01 0.85 1.17 1.16
Non-Cash Adjustments To Reconcile Net Income
0.45 1.80 1.34 1.11 1.46 1.33 -1.73 0.41 6.98 1.71 -0.56
Changes in Operating Assets and Liabilities, net
2.46 -2.71 3.42 5.23 0.85 2.39 7.03 8.35 -0.34 -1.95 3.05
Net Cash From Investing Activities
-2.34 -3.12 9.51 -28 2.30 -1.76 -0.50 -14 -0.11 0.06 -4.71
Net Cash From Continuing Investing Activities
-2.34 -3.12 9.51 -28 2.30 -1.76 -0.50 -14 -0.11 0.06 -4.71
Purchase of Property, Plant & Equipment
-0.14 -0.13 -0.28 -0.46 -0.25 -0.14 -0.10 -0.10 -0.28 -0.07 -0.10
Acquisitions
-2.56 -2.00 -1.21 -24 -5.77 -1.97 -0.25 -15 -0.17 -0.11 -2.56
Purchase of Investments
-7.53 -5.47 -2.38 -20 -12 0.00 - - - 0.00 -2.00
Other Investing Activities, net
- - - 0.00 0.00 0.36 -0.15 1.90 0.35 0.24 -0.05
Net Cash From Financing Activities
-5.19 -1.15 1.95 7.14 -5.08 -7.12 -3.55 -2.06 -7.42 0.20 -6.75
Net Cash From Continuing Financing Activities
-5.19 -1.15 1.95 7.14 -5.08 -6.32 -3.55 -2.06 -7.42 0.20 -6.75
Repayment of Debt
-1.67 0.00 -19 -46 -78 -63 -59 -52 -35 -36 -10
Repurchase of Common Equity
-5.34 -2.52 -3.75 -3.26 -3.49 -1.99 -1.39 -1.05 -0.74 -0.58 -0.26
Issuance of Debt
1.70 2.40 25 56 76 59 59 53 31 38 0.00
Issuance of Common Equity
- - 0.00 0.00 1.00 0.00 - - - 0.00 5.27
Other Financing Activities, net
0.11 -1.03 0.00 0.20 -1.03 -0.82 -2.17 -2.21 -3.27 -1.72 -1.71
Cash Interest Paid
0.03 0.02 0.01 0.10 0.20 0.22 0.06 0.52 0.65 0.57 0.44
Cash Income Taxes Paid
0.05 -0.01 0.02 0.02 0.02 -0.09 -0.00 0.00 0.11 0.02 -0.00

Quarterly Cash Flow Statements for Cumberland Pharmaceuticals

This table details how cash moves in and out of Cumberland Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 9/30/2026
Net Change in Cash & Equivalents
-0.19 0.23 -1.21 0.13 0.50 -2.86 0.98 -0.89 -3.75 -0.44 77
Net Cash From Operating Activities
1.04 -2.14 -0.86 0.48 1.90 3.90 0.84 0.19 0.00 0.39 -1.50
Net Cash From Continuing Operating Activities
1.04 -2.14 -0.86 0.48 1.90 3.90 0.84 0.19 0.00 0.39 2.36
Net Income / (Loss) Continuing Operations
-6.30 -1.90 -1.10 -1.54 -1.90 1.25 -0.74 -1.95 -1.43 -3.29 78
Consolidated Net Income / (Loss)
-6.30 -1.90 -1.10 -1.54 -1.90 1.25 -0.74 -1.95 -1.43 -3.29 78
Depreciation Expense
1.23 1.15 1.14 1.12 1.50 1.03 1.03 1.04 1.04 1.28 0.03
Amortization Expense
0.13 0.29 0.29 -0.56 1.15 0.29 0.29 0.29 0.29 0.29 0.24
Non-Cash Adjustments To Reconcile Net Income
9.24 -0.05 -0.33 0.40 1.69 -0.06 -0.48 -0.23 0.00 0.11 -80
Changes in Operating Assets and Liabilities, net
-3.26 -1.62 -0.85 1.05 -0.53 1.39 0.74 1.04 0.10 1.99 4.39
Net Cash From Discontinued Operating Activities
- - - - - - - - - - -3.86
Net Cash From Investing Activities
0.26 -0.06 -0.05 0.19 -0.03 -1.23 0.29 -0.69 -3.07 -0.06 100
Net Cash From Continuing Investing Activities
0.26 -0.06 -0.05 0.19 -0.03 -1.23 0.29 -0.69 -3.07 -0.06 -0.05
Purchase of Property, Plant & Equipment
-0.05 -0.04 -0.01 -0.02 -0.00 -0.05 -0.03 -0.02 0.00 0.00 -0.01
Acquisitions
-0.04 -0.02 -0.04 -0.03 -0.02 -0.02 0.31 -0.62 -1.07 -0.02 0.00
Other Investing Activities, net
0.35 - - - - -1.16 - - - -0.04 -0.04
Net Cash From Discontinued Investing Activities
- - - - - - - - - - 100
Net Cash From Financing Activities
-1.49 2.42 -0.31 -0.54 -1.38 -5.53 -0.15 -0.39 -0.68 -0.76 -22
Net Cash From Continuing Financing Activities
-1.49 2.42 -0.31 -0.54 -1.38 -5.53 -0.15 -0.39 -0.68 -0.76 -23
Repurchase of Common Equity
-0.19 -0.25 -0.13 -0.10 -0.10 -0.25 -0.01 -0.01 - -0.06 -0.26
Net Cash From Discontinued Financing Activities
- - - - - - - - - - 0.85

Annual Balance Sheets for Cumberland Pharmaceuticals

This table presents Cumberland Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
92 93 93 113 105 96 84 93 82 76 77
Total Current Assets
65 66 69 59 50 50 46 46 36 36 37
Cash & Equivalents
38 35 45 28 28 25 27 20 18 18 11
Accounts Receivable
6.08 7.33 8.40 7.84 7.86 12 6.88 13 9.76 12 17
Inventories, net
4.27 5.37 6.74 12 8.87 11 8.43 9.86 4.61 4.00 0.03
Prepaid Expenses
1.47 2.71 3.47 2.96 2.76 2.20 3.34 3.08 3.03 2.79 0.65
Other Current Assets
- - - - - - - - - - 0.00
Other Current Nonoperating Assets
- - - - 2.46 - - - - - 7.99
Plant, Property, & Equipment, net
0.54 0.46 0.53 0.77 0.75 0.57 0.44 0.28 0.37 0.28 0.26
Total Noncurrent Assets
27 27 24 53 54 46 38 47 46 39 39
Intangible Assets
21 22 21 34 31 28 24 31 23 18 0.05
Other Noncurrent Operating Assets
1.89 2.12 2.49 18 22 17 13 15 22 20 8.80
Other Noncurrent Nonoperating Assets
- - - - - - - - - - 31
Total Liabilities & Shareholders' Equity
92 93 93 113 105 96 84 93 82 76 77
Total Liabilities
15 20 29 57 53 50 42 57 53 53 52
Total Current Liabilities
12 15 18 28 24 26 19 29 28 32 37
Accounts Payable
2.88 8.04 8.98 11 9.99 13 9.64 11 14 14 19
Accrued Expenses
9.53 6.76 8.71 17 11 11 8.67 - - - 7.77
Other Current Liabilities
- - - - 0.92 1.02 0.97 18 14 13 3.32
Other Current Nonoperating Liabilities
- - - - 2.15 - - - - - 7.08
Total Noncurrent Liabilities
2.69 5.49 12 29 29 24 23 28 25 21 16
Long-Term Debt
1.70 4.10 9.80 20 19 15 15 16 13 10 5.24
Other Noncurrent Operating Liabilities
0.99 1.39 1.82 9.32 11 8.92 7.58 12 12 11 8.10
Other Noncurrent Nonoperating Liabilities
- - - - - - - - - - 2.20
Total Equity & Noncontrolling Interests
77 73 64 56 51 47 43 36 29 23 25
Total Preferred & Common Equity
77 73 64 56 51 47 43 36 30 23 25
Total Common Equity
77 73 64 56 51 47 43 36 30 23 25
Common Stock
57 55 52 51 50 49 48 47 47 47 52
Retained Earnings
20 19 12 4.75 1.21 -2.13 -5.64 -11 -17 -24 -27
Noncontrolling Interest
-0.07 -0.13 -0.20 -0.27 -0.04 -0.12 -0.21 -0.29 -0.34 -0.31 -0.34

Quarterly Balance Sheets for Cumberland Pharmaceuticals

This table presents Cumberland Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
88 82 79 77 70 68 66 71 63 114
Total Current Assets
42 36 36 35 32 31 30 33 34 105
Cash & Equivalents
19 19 17 17 15 16 15 11 3.86 81
Accounts Receivable
13 11 12 11 10 10 10 14 13 13
Inventories, net
8.67 4.33 4.30 4.51 4.10 3.22 2.93 5.45 0.03 0.03
Prepaid Expenses
- 2.68 2.32 1.95 2.18 1.58 1.38 2.07 0.68 0.63
Other Current Assets
1.97 - - - - - - - - 11
Other Current Nonoperating Assets
- - - - - - - - 16 0.19
Plant, Property, & Equipment, net
0.38 0.37 0.34 0.31 0.30 0.30 0.29 0.24 0.25 0.23
Total Noncurrent Assets
46 45 43 41 38 36 36 38 29 8.99
Intangible Assets
27 22 20 19 17 16 15 13 0.04 0.04
Other Noncurrent Operating Assets
18 22 21 21 20 20 20 24 10 8.95
Other Noncurrent Nonoperating Assets
- - - - - - - - 18 0.00
Total Liabilities & Shareholders' Equity
88 82 79 77 70 68 66 71 63 114
Total Liabilities
52 54 52 52 42 40 40 50 46 42
Total Current Liabilities
27 26 25 31 26 24 24 34 35 34
Accounts Payable
11 13 13 12 14 13 14 17 20 17
Accrued Expenses
- - - - - - - - 7.52 0.00
Other Current Liabilities
17 13 12 13 12 11 10 18 2.75 18
Other Current Nonoperating Liabilities
- - - - - - - - 5.38 0.00
Total Noncurrent Liabilities
25 28 28 21 16 16 16 15 11 7.27
Long-Term Debt
13 16 16 10 5.24 5.24 5.24 5.24 0.00 0.00
Other Noncurrent Operating Liabilities
12 12 12 11 11 11 11 9.96 8.19 7.27
Other Noncurrent Nonoperating Liabilities
- - - - - - - - 2.39 0.00
Total Equity & Noncontrolling Interests
36 27 26 24 28 28 26 21 17 72
Total Preferred & Common Equity
36 27 26 25 29 28 26 22 17 73
Total Common Equity
36 27 26 25 29 28 26 22 17 73
Common Stock
47 47 47 47 51 51 52 52 52 52
Retained Earnings
-11 -19 -21 -22 -23 -23 -25 -30 -34 21
Noncontrolling Interest
-0.34 -0.30 -0.32 -0.31 -0.32 -0.31 -0.32 -0.33 -0.33 -0.33

Annual Metrics And Ratios for Cumberland Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Cumberland Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
16,452,665.00 16,180,604.00 15,748,137.00 15,527,623.00 15,183,943.00 15,036,923.00 14,809,628.00 14,464,127.00 14,255,700.00 14,042,304.00 14,956,627.00
DEI Adjusted Shares Outstanding
16,452,665.00 16,180,604.00 15,748,137.00 15,527,623.00 15,183,943.00 15,036,923.00 14,809,628.00 14,464,127.00 14,255,700.00 14,042,304.00 14,956,627.00
DEI Earnings Per Adjusted Shares Outstanding
0.04 -0.06 -0.51 -0.45 -0.23 -0.22 -0.24 -0.39 -0.44 -0.46 -0.19
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-9.17% -1.47% 24.60% -28.69% 17.19% 8.88% -3.89% 16.75% -5.85% -4.26% 17.57%
EBITDA Growth
-39.06% -69.21% -229.32% -496.78% 40.22% 67.22% 46.39% 128.92% -148.02% -4.83% 2,134.72%
EBIT Growth
-68.76% -228.92% -184.79% -173.76% 16.87% 31.29% 13.97% 7.23% -15.91% -4.93% 54.93%
NOPAT Growth
-73.36% -267.68% -184.79% -173.76% 16.87% 31.29% -20.31% 25.69% -67.48% 32.68% 56.59%
Net Income Growth
-71.59% -249.59% -701.82% 12.56% 49.61% 3.60% -5.38% -56.82% -12.05% -1.78% 55.54%
EPS Growth
-71.43% -250.00% -733.33% 10.00% 48.89% 4.35% -9.09% -58.33% -15.79% -4.55% 58.70%
Operating Cash Flow Growth
-12.20% -90.31% -197.93% 658.12% -1.81% 77.17% 17.13% 33.28% -27.91% -110.05% 905.72%
Free Cash Flow Firm Growth
47.67% -362.51% 125.45% -4,052.72% 65.05% 93.61% 325.37% -593.85% 134.29% -131.83% 31.58%
Invested Capital Growth
-1.12% 5.19% -12.74% 66.44% 4.37% -9.60% -17.67% 6.07% -26.82% -16.29% -7.64%
Revenue Q/Q Growth
-3.71% 3.26% 6.66% -24.55% 26.50% 2.62% -5.12% 1.95% 0.58% 2.94% 7.86%
EBITDA Q/Q Growth
-19.67% -50.45% 7.48% -153.74% 37.13% 52.43% -213.76% 113.07% -104.02% 97.93% -25.04%
EBIT Q/Q Growth
-41.34% -357.75% 1.31% -85.25% 22.20% 20.53% -8.30% 34.54% -194.82% 42.47% 14.43%
NOPAT Q/Q Growth
-45.65% -357.75% 1.31% -85.25% 22.20% 20.53% -51.45% 26.68% -69.01% 40.27% 14.43%
Net Income Q/Q Growth
-43.66% -852.40% -0.65% -25.17% 26.29% 1.64% -468.26% 20.14% -154.40% 40.58% 14.17%
EPS Q/Q Growth
-42.86% 0.00% 0.00% -25.00% 25.81% 0.00% -500.00% 0.00% 0.00% 40.26% 17.39%
Operating Cash Flow Q/Q Growth
-19.37% -46.93% -177.28% 390.91% -48.39% -0.06% 21.12% 24.77% -29.89% 58.54% -27.83%
Free Cash Flow Firm Q/Q Growth
-26.90% -37.08% -73.40% -564.12% 71.31% -101.43% 103.01% 7.07% -23.51% -13.12% -108.79%
Invested Capital Q/Q Growth
-2.78% -3.17% 3.47% 77.50% -3.30% 0.00% -14.64% -11.55% -21.11% -14.02% 15.75%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
85.18% 81.96% 82.09% 79.50% 78.42% 76.89% 75.51% 78.29% 84.66% 82.61% 85.02%
EBITDA Margin
10.16% 3.17% -3.29% -27.57% -14.06% -4.23% -2.36% 0.59% -0.30% -0.33% 5.65%
Operating Margin
3.32% -4.34% -9.92% -38.07% -27.01% -17.04% -21.34% -13.58% -24.16% -16.99% -6.27%
EBIT Margin
3.32% -4.34% -9.92% -38.07% -27.01% -17.04% -15.26% -12.12% -14.93% -16.36% -6.27%
Profit (Net Income) Margin
2.00% -3.04% -19.56% -23.99% -10.31% -9.13% -10.01% -13.45% -16.01% -17.02% -6.43%
Tax Burden Percent
53.82% 75.21% 207.74% 65.15% 38.17% 52.04% 64.77% 101.23% 100.73% 99.65% 101.90%
Interest Burden Percent
112.17% 93.14% 94.94% 96.70% 100.03% 102.95% 101.31% 109.57% 106.45% 104.38% 100.69%
Effective Tax Rate
46.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
2.31% -3.80% -11.26% -24.84% -16.17% -11.43% -15.88% -12.68% -23.83% -20.66% -10.23%
ROIC Less NNEP Spread (ROIC-NNEP)
2.17% -3.80% 0.77% -27.61% -38.69% -22.03% -32.14% 8.56% -31.69% 26.53% 10.24%
Return on Net Nonoperating Assets (RNNOA)
-1.46% 2.46% -0.48% 13.06% 9.52% 4.45% 7.83% -1.70% 4.42% -4.21% -1.93%
Return on Equity (ROE)
0.85% -1.34% -11.75% -11.78% -6.65% -6.98% -8.05% -14.38% -19.41% -24.88% -12.17%
Cash Return on Invested Capital (CROIC)
3.44% -8.85% 2.35% -74.71% -20.45% -1.34% 3.50% -18.57% 7.14% -2.93% -2.29%
Operating Return on Assets (OROA)
1.19% -1.55% -4.37% -10.85% -8.55% -6.35% -6.07% -5.74% -6.76% -7.87% -3.66%
Return on Assets (ROA)
0.72% -1.08% -8.63% -6.84% -3.27% -3.40% -3.98% -6.37% -7.25% -8.19% -3.76%
Return on Common Equity (ROCE)
0.85% -1.34% -11.78% -11.83% -6.67% -6.99% -8.08% -14.47% -19.60% -25.19% -12.33%
Return on Equity Simple (ROE_SIMPLE)
0.87% -1.37% -12.55% -12.60% -6.94% -7.28% -8.41% -15.58% -21.39% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
0.60 -1.00 -2.86 -7.82 -6.50 -4.47 -5.37 -3.99 -6.69 -4.50 -1.95
NOPAT Margin
1.78% -3.04% -6.94% -26.65% -18.91% -11.93% -14.93% -9.51% -16.91% -11.89% -4.39%
Net Nonoperating Expense Percent (NNEP)
0.14% 0.00% -12.03% 2.77% 22.51% 10.60% 16.26% -21.24% 7.86% -47.20% -20.48%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -15.91% -11.90% -6.56%
Cost of Revenue to Revenue
14.82% 18.04% 17.91% 20.50% 21.58% 23.11% 24.49% 21.71% 15.34% 17.39% 14.98%
SG&A Expenses to Revenue
22.70% 25.92% 23.45% 34.59% 29.01% 27.23% 27.18% 24.23% 26.93% 29.38% 26.83%
R&D to Revenue
11.48% 9.66% 10.40% 25.82% 19.97% 15.42% 15.80% 15.92% 14.75% 12.72% 12.50%
Operating Expenses to Revenue
81.86% 86.30% 92.01% 117.57% 105.43% 93.93% 96.85% 91.87% 108.82% 99.59% 91.30%
Earnings before Interest and Taxes (EBIT)
1.11 -1.43 -4.08 -11 -9.29 -6.38 -5.49 -5.09 -5.90 -6.20 -2.79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
3.40 1.05 -1.36 -8.09 -4.84 -1.59 -0.85 0.25 -0.12 -0.12 2.52
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.13 1.22 1.81 1.68 1.53 0.94 1.62 0.90 0.86 1.46 2.39
Price to Tangible Book Value (P/TBV)
1.55 1.74 2.72 4.37 4.05 2.47 3.85 6.83 4.20 8.39 5.99
Price to Revenue (P/Rev)
2.58 2.69 2.82 3.19 2.27 1.18 1.92 0.77 0.65 0.88 1.34
Price to Earnings (P/E)
118.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.37 1.58 3.19 1.96 1.67 0.93 1.86 0.89 0.83 1.53 2.89
Enterprise Value to Revenue (EV/Rev)
1.06 1.30 1.83 2.63 1.99 0.92 1.58 0.68 0.50 0.80 1.19
Enterprise Value to EBITDA (EV/EBITDA)
10.40 40.86 0.00 0.00 0.00 0.00 0.00 116.76 0.00 0.00 21.05
Enterprise Value to EBIT (EV/EBIT)
31.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
59.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
6.02 75.22 0.00 24.78 22.40 6.37 8.97 3.39 3.23 0.00 10.74
Enterprise Value to Free Cash Flow (EV/FCFF)
39.74 0.00 126.72 0.00 0.00 0.00 48.05 0.00 9.80 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.02 0.06 0.15 0.36 0.36 0.32 0.35 0.45 0.44 0.68 0.21
Long-Term Debt to Equity
0.02 0.06 0.15 0.36 0.36 0.32 0.35 0.45 0.44 0.45 0.21
Financial Leverage
-0.67 -0.65 -0.63 -0.47 -0.25 -0.20 -0.24 -0.20 -0.14 -0.16 -0.19
Leverage Ratio
1.19 1.24 1.36 1.72 2.04 2.05 2.02 2.26 2.68 3.04 3.24
Compound Leverage Factor
1.33 1.15 1.29 1.67 2.04 2.11 2.05 2.47 2.85 3.17 3.26
Debt to Total Capital
2.17% 5.31% 13.29% 26.47% 26.59% 24.24% 26.04% 31.05% 30.41% 40.39% 17.60%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.48% 0.00%
Long-Term Debt to Total Capital
2.17% 5.31% 13.29% 26.47% 26.59% 24.24% 26.04% 31.05% 30.41% 26.91% 17.60%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
-0.09% -0.17% -0.27% -0.36% -0.05% -0.19% -0.37% -0.56% -0.82% -0.81% -1.13%
Common Equity to Total Capital
97.92% 94.86% 86.98% 73.90% 73.47% 75.95% 74.33% 69.51% 70.41% 60.42% 83.53%
Debt to EBITDA
0.50 3.91 -7.23 -2.47 -3.83 -9.46 -17.65 65.92 -108.33 -123.48 2.08
Net Debt to EBITDA
-15.00 -43.91 29.72 2.01 2.01 6.15 14.17 -14.48 46.92 21.73 -2.46
Long-Term Debt to EBITDA
0.50 3.91 -7.23 -2.47 -3.83 -9.46 -17.65 65.92 -108.33 -82.26 2.08
Debt to NOPAT
2.84 -4.09 -3.43 -2.56 -2.85 -3.36 -2.79 -4.06 -1.91 -3.39 -2.68
Net Debt to NOPAT
-85.36 45.89 14.10 2.08 1.49 2.18 2.24 0.89 0.83 0.60 3.17
Long-Term Debt to NOPAT
2.84 -4.09 -3.43 -2.56 -2.85 -3.36 -2.79 -4.06 -1.91 -2.26 -2.68
Altman Z-Score
4.82 3.87 3.50 1.31 1.23 0.98 1.48 0.67 0.35 0.24 0.66
Noncontrolling Interest Sharing Ratio
-0.05% -0.13% -0.24% -0.40% -0.29% -0.16% -0.37% -0.64% -0.97% -1.26% -1.37%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
5.20 4.43 3.88 2.13 2.08 1.95 2.37 1.61 1.28 1.15 1.01
Quick Ratio
4.74 3.88 3.31 1.59 1.49 1.45 1.76 1.15 1.00 0.94 0.77
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.89 -2.34 0.60 -24 -8.22 -0.53 1.18 -5.85 2.01 -0.64 -0.44
Operating Cash Flow to CapEx
4,110.70% 435.14% -202.10% 683.26% 1,241.40% 3,845.46% 6,126.07% 8,275.64% 2,166.55% -921.12% 5,038.17%
Free Cash Flow to Firm to Interest Expense
12.06 -21.98 6.41 -120.12 -33.40 -1.99 12.08 -9.98 3.00 -1.05 -0.88
Operating Cash Flow to Interest Expense
79.57 5.35 -6.00 15.89 12.41 20.54 64.70 14.43 9.12 -1.01 9.94
Operating Cash Flow Less CapEx to Interest Expense
77.64 4.12 -8.97 13.57 11.41 20.01 63.64 14.25 8.70 -1.12 9.75
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.36 0.36 0.44 0.29 0.32 0.37 0.40 0.47 0.45 0.48 0.58
Accounts Receivable Turnover
5.79 4.93 5.23 3.61 4.38 3.70 3.74 4.19 3.45 3.53 3.11
Inventory Turnover
1.01 1.24 1.22 0.64 0.71 0.89 0.92 1.00 0.84 1.53 1.30
Fixed Asset Turnover
56.45 65.99 82.85 45.14 45.28 56.64 70.78 115.63 121.34 117.37 164.26
Accounts Payable Turnover
1.62 1.09 0.87 0.60 0.70 0.74 0.77 0.89 0.49 0.47 0.41
Days Sales Outstanding (DSO)
63.06 74.09 69.74 100.99 83.34 98.64 97.65 87.06 105.76 103.42 117.43
Days Inventory Outstanding (DIO)
362.58 295.31 299.84 570.73 515.18 411.47 394.94 366.13 435.39 238.57 279.90
Days Payable Outstanding (DPO)
224.82 334.27 421.34 608.85 518.55 493.31 477.15 409.49 747.75 774.56 889.12
Cash Conversion Cycle (CCC)
200.82 35.12 -51.76 62.87 79.96 16.80 15.44 43.70 -206.61 -432.57 -491.79
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
26 27 24 39 41 37 31 32 24 20 18
Invested Capital Turnover
1.29 1.25 1.62 0.93 0.86 0.96 1.06 1.33 1.41 1.74 2.33
Increase / (Decrease) in Invested Capital
-0.29 1.34 -3.45 16 1.72 -3.94 -6.56 1.85 -8.69 -3.86 -1.52
Enterprise Value (EV)
35 43 75 77 68 34 57 29 20 30 53
Market Capitalization
87 89 116 94 78 44 69 33 26 33 60
Book Value per Share
$4.67 $4.53 $4.07 $3.60 $3.37 $3.13 $2.89 $2.51 $2.08 $1.63 $1.66
Tangible Book Value per Share
$3.39 $3.16 $2.71 $1.38 $1.27 $1.20 $1.21 $0.33 $0.43 $0.28 $0.66
Total Capital
79 77 74 76 70 62 58 52 42 38 30
Total Debt
1.70 4.10 9.80 20 19 15 15 16 13 15 5.24
Total Long-Term Debt
1.70 4.10 9.80 20 19 15 15 16 13 10 5.24
Net Debt
-51 -46 -40 -16 -9.71 -9.75 -12 -3.56 -5.54 -2.69 -6.20
Capital Expenditures (CapEx)
0.14 0.13 0.28 0.46 0.25 0.14 0.10 0.10 0.28 0.07 0.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-0.60 0.62 0.90 -4.92 -2.20 -0.45 -0.63 -2.47 -11 -8.03 -11
Debt-free Net Working Capital (DFNWC)
52 51 51 31 26 24 26 17 7.73 9.93 0.32
Net Working Capital (NWC)
52 51 51 31 26 24 26 17 7.73 4.83 0.32
Net Nonoperating Expense (NNE)
-0.07 0.00 5.19 -0.78 -2.96 -1.05 -1.77 1.66 -0.36 1.94 0.91
Net Nonoperating Obligations (NNO)
-51 -46 -40 -16 -10 -9.75 -12 -3.56 -5.54 -2.69 -6.20
Total Depreciation and Amortization (D&A)
2.29 2.48 2.73 3.08 4.45 4.80 4.64 5.34 5.79 6.07 5.31
Debt-free, Cash-free Net Working Capital to Revenue
-1.78% 1.88% 2.20% -16.76% -6.40% -1.21% -1.76% -5.87% -26.77% -21.22% -25.00%
Debt-free Net Working Capital to Revenue
155.65% 153.68% 123.91% 106.70% 75.64% 64.91% 73.39% 41.16% 19.55% 26.22% 0.71%
Net Working Capital to Revenue
155.65% 153.68% 123.91% 106.70% 75.64% 64.91% 73.39% 41.16% 19.55% 12.76% 0.71%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.04 ($0.06) ($0.50) ($0.45) ($0.23) ($0.22) ($0.24) ($0.38) ($0.44) ($0.46) ($0.19)
Adjusted Weighted Average Basic Shares Outstanding
16.72M 16.24M 15.91M 15.61M 15.40M 15.16M 14.90M 14.56M 14.30M 14.06M 14.85M
Adjusted Diluted Earnings per Share
$0.04 ($0.06) ($0.50) ($0.45) ($0.23) ($0.22) ($0.24) ($0.38) ($0.44) ($0.46) ($0.19)
Adjusted Weighted Average Diluted Shares Outstanding
17.09M 16.24M 15.91M 15.61M 15.40M 15.16M 14.90M 14.56M 14.30M 14.06M 14.85M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
16.31M 16.01M 15.65M 15.45M 15.18M 14.92M 14.84M 14.40M 14.18M 13.97M 14.96M
Normalized Net Operating Profit after Tax (NOPAT)
0.60 -1.00 -2.86 -7.82 -6.50 -4.47 -5.37 -3.99 -6.69 -4.50 -1.95
Normalized NOPAT Margin
1.78% -3.04% -6.94% -26.65% -18.91% -11.93% -14.93% -9.51% -16.91% -11.89% -4.39%
Pre Tax Income Margin
3.72% -4.04% -9.42% -36.82% -27.02% -17.55% -15.46% -13.29% -15.89% -17.08% -6.31%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
15.05 -13.47 -43.93 -57.05 -37.73 -24.21 -56.01 -8.69 -8.84 -10.23 -5.63
NOPAT to Interest Expense
8.10 -9.43 -30.75 -39.93 -26.41 -16.94 -54.82 -6.81 -10.01 -7.44 -3.94
EBIT Less CapEx to Interest Expense
13.12 -14.70 -46.90 -59.38 -38.73 -24.74 -57.06 -8.87 -9.26 -10.34 -5.83
NOPAT Less CapEx to Interest Expense
6.16 -10.66 -33.72 -42.26 -27.41 -17.48 -55.88 -6.99 -10.44 -7.55 -4.14
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
795.55% -251.08% -46.61% -46.35% -98.55% -58.12% -38.49% -18.64% -11.70% -8.99% -9.20%

Quarterly Metrics And Ratios for Cumberland Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Cumberland Pharmaceuticals' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
14,176,529.00 14,191,229.00 14,095,548.00 14,042,304.00 13,968,394.00 14,961,137.00 14,959,937.00 14,956,627.00 14,956,627.00 14,983,107.00 14,983,107.00
DEI Adjusted Shares Outstanding
14,176,529.00 14,191,229.00 14,095,548.00 14,042,304.00 13,968,394.00 14,961,137.00 14,959,937.00 14,956,627.00 14,956,627.00 14,983,107.00 14,983,107.00
DEI Earnings Per Adjusted Shares Outstanding
-0.14 -0.08 -0.11 -0.14 0.09 -0.05 -0.13 -0.09 -0.22 -0.29 5.19
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-7.88% -9.55% -9.92% 11.57% 37.84% 10.04% -8.73% 31.08% -22.04% -56.29% 1,155.00%
EBITDA Growth
-124.58% -83.92% -302.07% 116.69% 708.53% 43.25% 29.31% -104.60% -159.78% 18.78% 35.80%
EBIT Growth
-692.68% -202.19% -39.49% 70.19% 169.12% 27.20% -34.85% 25.56% -342.22% -1.31% 32.21%
NOPAT Growth
11.13% -3,269.28% 9.22% 70.19% 198.29% 27.20% -15.98% 25.56% -270.32% -1.31% 32.21%
Net Income Growth
-1,204.25% -227.89% -44.56% 69.82% 165.61% 33.32% -26.81% 24.87% -363.35% -481.39% 4,090.56%
EPS Growth
-1,500.00% -233.33% -57.14% 70.45% 157.14% 37.50% -18.18% 30.77% -375.00% -480.00% 4,000.00%
Operating Cash Flow Growth
-50.66% -116.34% -61.55% 83.12% 282.46% 198.61% -60.64% -99.84% -90.07% 0.00% -900.31%
Free Cash Flow Firm Growth
53.50% -24.71% 9.79% -41.05% 7.98% 19.29% 1.51% -78.34% -90.10% 380.28% 339.58%
Invested Capital Growth
-30.81% -21.90% -23.19% -16.29% -37.16% -32.09% -31.40% -7.64% -15.90% -177.82% -154.26%
Revenue Q/Q Growth
-9.15% 15.90% -7.75% 14.86% 12.24% -7.48% -23.48% 64.95% -33.24% 0.00% 1,195.44%
EBITDA Q/Q Growth
91.08% 193.76% -323.68% 189.24% 225.12% -77.93% -210.39% 94.19% -4,120.87% 0.00% 47.18%
EBIT Q/Q Growth
69.75% 45.07% -41.95% -26.40% 170.14% -157.86% -162.92% 30.23% -128.22% 0.00% 38.73%
NOPAT Q/Q Growth
69.75% 45.07% -65.04% -8.71% 199.74% -140.68% -162.92% 30.23% -128.22% 0.00% 38.73%
Net Income Q/Q Growth
69.81% 42.04% -39.39% -23.73% 165.64% -158.90% -165.10% 26.70% -130.08% 0.00% 1,919.61%
EPS Q/Q Growth
68.18% 42.86% -37.50% -18.18% 161.54% -162.50% -160.00% 30.77% -144.44% 0.00% 1,848.28%
Operating Cash Flow Q/Q Growth
-305.42% 59.95% 155.57% 300.55% 104.69% -78.36% -77.82% -98.38% 12,698.45% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth
122.08% -35.78% -7.09% -55.51% 306.79% -1.41% -20.94% -90.51% -97.51% 0.00% -16.71%
Invested Capital Q/Q Growth
4.23% 0.25% -6.82% -14.02% -21.76% -8.88% -5.87% 15.75% 240.97% 0.00% 34.36%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
81.46% 82.63% 85.44% 81.06% 87.83% 81.44% 88.08% 83.61% 78.82% 100.00% 100.00%
EBITDA Margin
-5.06% 4.09% -9.92% 7.70% 22.32% 5.32% -7.68% -0.27% -17.11% -1,894.36% -77.24%
Operating Margin
-22.00% -10.42% -18.65% -17.65% 11.03% -6.90% -23.70% -10.02% -34.27% -1,898.65% -89.80%
EBIT Margin
-22.00% -10.42% -16.04% -17.65% 11.03% -6.90% -23.70% -10.02% -34.27% -1,898.65% -89.80%
Profit (Net Income) Margin
-22.39% -11.20% -16.92% -18.22% 10.66% -6.78% -23.50% -10.44% -36.00% -2,567.87% 3,606.91%
Tax Burden Percent
100.61% 101.05% 100.75% 97.09% 99.55% 100.78% 100.29% 102.62% 104.78% 137.87% -6,955.62%
Interest Burden Percent
101.17% 106.28% 104.68% 106.33% 97.05% 97.60% 98.89% 101.53% 100.25% 98.10% 57.74%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-19.78% -9.76% -18.06% -21.47% 22.41% -9.76% -35.17% -16.36% -59.17% 0.00% -758.29%
ROIC Less NNEP Spread (ROIC-NNEP)
22.98% 2.34% -7.98% -6.59% 23.33% -6.25% -25.05% -5.81% -45.14% 0.00% -932.73%
Return on Net Nonoperating Assets (RNNOA)
-1.01% -0.24% 0.92% 1.05% -3.96% 1.41% 5.65% 1.10% 14.22% 0.00% 863.74%
Return on Equity (ROE)
-20.79% -9.99% -17.14% -20.43% 18.45% -8.35% -29.53% -15.26% -44.95% 0.00% 105.45%
Cash Return on Invested Capital (CROIC)
13.51% -2.51% -2.12% -2.93% 34.27% 28.16% 25.51% -2.29% -12.42% 0.00% 0.00%
Operating Return on Assets (OROA)
-9.99% -4.69% -7.17% -8.50% 5.94% -3.96% -13.72% -5.86% -20.40% 0.00% -43.69%
Return on Assets (ROA)
-10.17% -5.04% -7.57% -8.77% 5.74% -3.90% -13.60% -6.10% -21.43% 0.00% 1,754.89%
Return on Common Equity (ROCE)
-20.99% -10.09% -17.33% -20.68% 18.69% -8.45% -29.90% -15.47% -45.54% 0.00% 106.15%
Return on Equity Simple (ROE_SIMPLE)
-30.58% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-1.31 -0.72 -1.19 -1.29 1.29 -0.52 -1.38 -0.96 -2.19 -2.21 -1.36
NOPAT Margin
-15.40% -7.30% -13.05% -12.36% 10.98% -4.83% -16.59% -7.02% -23.99% -1,329.06% -62.86%
Net Nonoperating Expense Percent (NNEP)
-42.76% -12.10% -10.09% -14.89% -0.92% -3.51% -10.12% -10.54% -14.03% -10.05% 174.44%
Return On Investment Capital (ROIC_SIMPLE)
-3.02% -1.71% -2.92% -3.41% 4.85% -1.59% -4.43% -3.22% -8.25% -12.93% -1.88%
Cost of Revenue to Revenue
18.54% 17.37% 14.56% 18.94% 12.17% 18.56% 11.92% 16.39% 21.18% 0.00% 0.00%
SG&A Expenses to Revenue
27.87% 27.99% 29.45% 31.88% 21.03% 26.53% 31.02% 29.51% 27.97% 1,530.48% 101.20%
R&D to Revenue
13.63% 10.75% 14.38% 12.39% 11.06% 13.55% 15.11% 11.33% 15.97% 463.88% 39.01%
Operating Expenses to Revenue
103.46% 93.05% 104.09% 98.71% 76.80% 88.34% 111.78% 93.64% 113.09% 1,998.65% 189.80%
Earnings before Interest and Taxes (EBIT)
-1.87 -1.03 -1.46 -1.84 1.29 -0.75 -1.97 -1.37 -3.13 -3.16 -1.94
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-0.43 0.40 -0.90 0.80 2.61 0.58 -0.64 -0.04 -1.56 -3.15 -1.67
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.87 0.82 0.73 1.46 2.73 1.79 1.79 2.39 1.74 4.32 1.62
Price to Tangible Book Value (P/TBV)
4.71 4.36 4.05 8.39 7.45 4.52 4.58 5.99 4.75 4.33 1.62
Price to Revenue (P/Rev)
0.61 0.57 0.49 0.88 1.44 1.19 1.13 1.34 0.90 0.00 2.68
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.71
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 58.64%
Enterprise Value to Invested Capital (EV/IC)
0.85 0.81 0.71 1.53 3.41 2.31 2.30 2.89 2.03 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.54 0.53 0.44 0.80 1.29 0.93 0.88 1.19 0.75 0.00 0.83
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 18.10 13.64 10.84 21.05 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
3.92 0.00 0.00 0.00 27.72 5.47 5.33 10.74 22.23 95.31 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
5.15 0.00 0.00 0.00 7.68 6.65 7.33 0.00 0.00 0.00 1.82
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.59 0.62 0.66 0.68 0.25 0.19 0.20 0.21 0.25 0.00 0.00
Long-Term Debt to Equity
0.59 0.62 0.41 0.45 0.25 0.19 0.20 0.21 0.25 0.00 0.00
Financial Leverage
-0.04 -0.10 -0.12 -0.16 -0.17 -0.23 -0.23 -0.19 -0.31 -0.92 -0.93
Leverage Ratio
2.70 2.67 2.74 3.04 3.14 2.73 2.84 3.24 2.84 2.92 1.83
Compound Leverage Factor
2.74 2.84 2.86 3.23 3.05 2.66 2.81 3.29 2.85 2.86 1.06
Debt to Total Capital
37.17% 38.20% 39.67% 40.39% 19.74% 15.92% 16.88% 17.60% 19.74% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 14.77% 13.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
37.17% 38.20% 24.91% 26.91% 19.74% 15.92% 16.88% 17.60% 19.74% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
-0.69% -0.75% -0.76% -0.81% -1.26% -0.94% -1.03% -1.13% -1.26% -1.94% -0.46%
Common Equity to Total Capital
63.52% 62.55% 61.09% 60.42% 81.51% 85.02% 84.15% 83.53% 81.51% 101.94% 100.46%
Debt to EBITDA
-3.92 -3.08 -2.69 -123.48 1.79 1.83 1.56 2.08 -3.16 0.00 0.00
Net Debt to EBITDA
0.60 0.24 0.23 21.73 -1.97 -3.80 -2.96 -2.46 3.47 0.00 0.00
Long-Term Debt to EBITDA
-3.92 -3.08 -1.69 -82.26 1.79 1.83 1.56 2.08 -3.16 0.00 0.00
Debt to NOPAT
-2.32 -2.10 -2.13 -3.39 -2.29 -2.50 -2.29 -2.68 -1.04 0.00 0.00
Net Debt to NOPAT
0.36 0.16 0.18 0.60 2.52 5.18 4.36 3.17 1.14 0.00 0.00
Long-Term Debt to NOPAT
-2.32 -2.10 -1.34 -2.26 -2.29 -2.50 -2.29 -2.68 -1.04 0.00 0.00
Altman Z-Score
0.47 0.49 0.29 0.43 0.73 0.98 0.79 0.72 0.28 0.00 3.02
Noncontrolling Interest Sharing Ratio
-0.97% -1.02% -1.07% -1.26% -1.31% -1.17% -1.25% -1.37% -1.31% 0.00% -0.66%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.37 1.44 1.13 1.15 0.95 1.30 1.23 1.01 0.95 0.96 3.05
Quick Ratio
1.10 1.17 0.93 0.94 0.73 1.10 1.05 0.77 0.73 0.49 2.71
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
9.70 6.23 5.79 2.57 10 7.43 5.88 0.56 0.75 28 23
Operating Cash Flow to CapEx
-5,133.58% -11,920.59% 3,091.90% 83,426.11% 8,185.00% 3,185.84% 786.87% 0.00% 0.00% 0.00% -15,267.20%
Free Cash Flow to Firm to Interest Expense
81.85 49.31 42.14 11.53 63.95 67.84 53.56 4.94 8.69 38,285.31 5,014.50
Operating Cash Flow to Interest Expense
-18.03 -6.77 3.46 8.53 23.80 7.70 1.71 0.03 4.51 0.00 -325.37
Operating Cash Flow Less CapEx to Interest Expense
-18.38 -6.83 3.35 8.52 23.51 7.46 1.49 0.03 4.51 0.00 -327.50
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.45 0.45 0.45 0.48 0.54 0.57 0.58 0.58 0.60 0.00 0.49
Accounts Receivable Turnover
3.08 3.17 3.07 3.53 3.30 3.84 3.80 3.11 3.39 0.00 3.81
Inventory Turnover
0.88 0.86 0.93 1.53 1.32 1.79 1.72 1.30 1.50 0.00 4.84
Fixed Asset Turnover
107.20 104.75 106.71 117.37 135.39 132.53 136.37 164.26 156.46 0.00 166.35
Accounts Payable Turnover
0.53 0.56 0.54 0.47 0.43 0.52 0.49 0.41 0.47 0.00 0.47
Days Sales Outstanding (DSO)
118.34 115.14 118.73 103.42 110.65 95.16 96.12 117.43 107.70 0.00 95.77
Days Inventory Outstanding (DIO)
414.22 422.30 391.79 238.57 277.36 203.86 212.20 279.90 242.97 0.00 75.40
Days Payable Outstanding (DPO)
693.75 649.37 680.00 774.56 839.69 703.13 738.01 889.12 774.84 0.00 771.55
Cash Conversion Cycle (CCC)
-161.20 -111.93 -169.48 -432.57 -451.68 -404.11 -429.68 -491.79 -424.18 0.00 -600.38
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
25 25 23 20 16 17 16 18 16 -13 -8.60
Invested Capital Turnover
1.28 1.34 1.38 1.74 2.04 2.02 2.12 2.33 2.47 0.00 12.06
Increase / (Decrease) in Invested Capital
-11 -6.95 -6.97 -3.86 -9.19 -7.95 -7.25 -1.52 -2.94 -30 -24
Enterprise Value (EV)
21 20 16 30 53 39 36 53 32 71 36
Market Capitalization
24 22 18 33 59 50 47 60 38 75 117
Book Value per Share
$1.94 $1.86 $1.76 $1.63 $1.55 $1.87 $1.75 $1.66 $1.45 $1.16 $4.84
Tangible Book Value per Share
$0.36 $0.35 $0.32 $0.28 $0.57 $0.74 $0.68 $0.66 $0.53 $1.16 $4.84
Total Capital
43 42 41 38 27 33 31 30 27 17 72
Total Debt
16 16 16 15 5.24 5.24 5.24 5.24 5.24 0.00 0.00
Total Long-Term Debt
16 16 10 10 5.24 5.24 5.24 5.24 5.24 0.00 0.00
Net Debt
-2.46 -1.24 -1.37 -2.69 -5.77 -11 -9.96 -6.20 -5.77 -3.86 -81
Capital Expenditures (CapEx)
0.04 0.01 0.02 0.00 0.05 0.03 0.02 -0.00 0.00 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-8.77 -6.51 -7.33 -8.03 -13 -8.85 -9.57 -11 -13 -5.41 -10
Debt-free Net Working Capital (DFNWC)
9.78 11 10 9.93 -1.70 7.23 5.63 0.32 -1.70 -1.55 70
Net Working Capital (NWC)
9.78 11 4.15 4.83 -1.70 7.23 5.63 0.32 -1.70 -1.55 70
Net Nonoperating Expense (NNE)
0.59 0.38 0.35 0.61 0.04 0.21 0.57 0.47 1.10 2.06 -79
Net Nonoperating Obligations (NNO)
-2.46 -1.24 -1.37 -2.69 -5.77 -11 -9.96 -6.20 -5.77 -30 -81
Total Depreciation and Amortization (D&A)
1.44 1.43 0.56 2.65 1.32 1.32 1.33 1.33 1.57 0.01 0.27
Debt-free, Cash-free Net Working Capital to Revenue
-22.58% -17.23% -19.92% -21.22% -30.93% -21.05% -23.18% -25.00% -30.30% 0.00% -23.68%
Debt-free Net Working Capital to Revenue
25.19% 28.65% 27.56% 26.22% -4.14% 17.19% 13.64% 0.71% -4.05% 0.00% 160.68%
Net Working Capital to Revenue
25.19% 28.65% 11.28% 12.76% -4.14% 17.19% 13.64% 0.71% -4.05% 0.00% 160.68%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.14) ($0.08) ($0.11) ($0.13) $0.08 ($0.05) ($0.13) ($0.09) ($0.22) ($0.29) $5.19
Adjusted Weighted Average Basic Shares Outstanding
14.10M 14.12M 14.05M 14.06M 14.94M 14.96M 14.96M 14.85M 14.96M 14.98M 14.99M
Adjusted Diluted Earnings per Share
($0.14) ($0.08) ($0.11) ($0.13) $0.08 ($0.05) ($0.13) ($0.09) ($0.22) ($0.29) $5.07
Adjusted Weighted Average Diluted Shares Outstanding
14.10M 14.12M 14.05M 14.06M 15.26M 14.96M 14.96M 14.85M 14.96M 14.98M 15.34M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
14.19M 14.10M 14.04M 13.97M 14.98M 14.96M 14.96M 14.96M 14.98M 14.98M 15.00M
Normalized Net Operating Profit after Tax (NOPAT)
-1.31 -0.72 -1.19 -1.29 1.29 -0.52 -1.38 -0.96 -2.19 -2.21 -1.36
Normalized NOPAT Margin
-15.40% -7.30% -13.05% -12.36% 10.98% -4.83% -16.59% -7.02% -23.99% -1,329.06% -62.86%
Pre Tax Income Margin
-22.25% -11.08% -16.79% -18.77% 10.70% -6.73% -23.44% -10.18% -34.36% -1,862.51% -51.86%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-15.77 -8.13 -10.61 -8.25 7.89 -6.82 -17.92 -12.14 -36.46 -4,365.28 -420.61
NOPAT to Interest Expense
-11.04 -5.69 -8.63 -5.78 7.85 -4.78 -12.54 -8.50 -25.52 -3,055.69 -294.43
EBIT Less CapEx to Interest Expense
-16.12 -8.18 -10.72 -8.26 7.60 -7.07 -18.13 -12.14 -36.46 0.00 -422.74
NOPAT Less CapEx to Interest Expense
-11.39 -5.75 -8.75 -5.79 7.56 -5.02 -12.76 -8.50 -25.52 0.00 -296.56
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-9.53% -7.45% -6.18% -8.99% -11.92% -15.39% -10.84% -9.20% -1.06% 0.00% 0.46%

Financials Breakdown Chart

Key Financial Trends

Cumberland Pharmaceuticals’ financial performance remains under pressure. Revenue has been highly volatile, ranging from $8.3 million to $13.7 million in the reported quarters from Q3 2023 through Q1 2026, before falling to $166,000 in Q2 2026. The Q2 figure is also accompanied by zero reported cost of revenue, suggesting a significant change in revenue mix, timing, or classification that investors should investigate. Operating losses have been common, including a $3.2 million loss in Q1 2026 and a $3.2 million loss in Q2 2026.

The company has made progress reducing debt, but its liquidity position has weakened. Long-term debt declined from $16.1 million in Q1 2024 to $5.2 million in Q1 2026 and was reported at zero in Q2 2026. However, cash and equivalents fell from $18.5 million in Q1 2024 to $3.9 million in Q2 2026. Total equity also declined to $17.1 million from $27.2 million in Q1 2024, while retained earnings remained deeply negative.

Cash flow has been mixed. Operating cash flow was positive in each provided quarter from Q2 2025 through Q1 2026, but it declined from $3.9 million in Q1 2025 to only $387,000 in Q1 2026. The latest balance sheet shows current liabilities of $35.2 million versus current assets of $33.6 million, highlighting a relatively tight short-term liquidity position despite the absence of reported long-term debt.

  • Debt reduction: Reported long-term debt fell to zero by Q2 2026, compared with $5.2 million in Q1 2026 and $16.1 million in Q1 2024, which could reduce future interest expense and refinancing risk.
  • Positive operating cash flow: The company generated positive operating cash flow in Q2 2025, Q3 2025, Q4 2025, and Q1 2026, indicating that operations have continued to provide some cash even while earnings were negative.
  • Gross-margin potential: Q1 2026 revenue of $9.1 million produced $7.2 million of gross profit, while Q2 2026 reported no cost of revenue. If sustainable, the reported cost structure could support stronger margins, although the Q2 data requires clarification.
  • Revenue remains inconsistent: Quarterly revenue rose to $13.7 million in Q4 2025 but dropped to $9.1 million in Q1 2026 and just $166,000 in Q2 2026, making near-term revenue trends difficult to assess.
  • Reported figures include restatements and calculated periods: Several historical statements are identified as restated or calculated, so comparisons across periods should be made cautiously.
  • Recurring operating losses: Cumberland reported operating losses in Q3 2023, Q4 2023, Q1 through Q4 2024, Q2 through Q4 2025, and Q1 and Q2 2026, with only Q1 2025 showing a reported operating profit.
  • Large Q2 2026 net loss: Net loss attributable to common shareholders widened to $4.3 million, or $0.29 per share, in Q2 2026 from $3.3 million, or $0.22 per share, in Q1 2026.
  • Cash balance deterioration: Cash declined from $18.5 million in Q1 2024 to $3.9 million in Q2 2026, limiting the company’s flexibility to fund operations, research, or acquisitions.
  • Tight working-capital position: Q2 2026 current liabilities of $35.2 million exceeded current assets of $33.6 million. Accounts payable alone totaled $19.6 million, creating additional pressure on near-term cash management.
  • Declining equity base: Total equity and noncontrolling interests fell to $17.1 million in Q2 2026 from $28.3 million in Q1 2024, while retained earnings reached a deficit of $34.4 million.
11/17/26 12:30 PM ETAI Generated. May Contain Errors.

Cumberland Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Cumberland Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Cumberland Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$2.86 million in 2025, compared with $671.11 thousand in 2015. The previous period was -$6.44 million in 2024. See where experts think Cumberland Pharmaceuticals is headed by visiting Cumberland Pharmaceuticals' forecast page.

Cumberland Pharmaceuticals' total operating income in 2025 was -$2.79 million, based on the following breakdown:
  • Total Gross Profit: $37.85 million
  • Total Operating Expenses: $40.65 million

Over the last 10 years, Cumberland Pharmaceuticals' total revenue changed from $33.52 million in 2015 to $44.52 million in 2025, a change of 32.8%.

In the past 12 quarters, Cumberland Pharmaceuticals' cash and equivalents has ranged from $3.86 million in Q2 2026 to $80.58 million in Q3 2026, and is currently $80.58 million as of their latest financial filing in Q3 2026.

Cumberland Pharmaceuticals had total debt of $5.24 million at the end of 2025, a 65.7% decrease from 2024, and a 208.3% increase since 2015.

Over the last 10 years, Cumberland Pharmaceuticals' book value per share changed from 4.67 in 2015 to 1.66 in 2025, a change of -64.4%.



Financial statements for NASDAQ:CPIX last updated on 11/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners